Acción NBY NOVABAY PHARMACEUTICALS, INC.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas NovaBay Pharmaceuticals, Inc.

Acciones

NBY

US66987P4090

Mercado cerrado - Nyse
Otros sitios de cotización
 22:00:00 14/06/2024 		Varia. Cinco días. Varia. 1 de enero.
2,51 USD -2,33 % Gráfico intradía de NovaBay Pharmaceuticals, Inc. -7,38 % -64,85 %
09/05 NovaBay Pharmaceuticals, Inc. Resultados del primer trimestre finalizado el 31 de marzo de 2024 CI
09/05 Transcript : NovaBay Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 09, 2024

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
NovaBay Pharmaceuticals Plan of Compliance Accepted by the NYSE American
NovaBay Pharmaceuticals Announces Approval of All Proposals at its 2024 Annual Meeting of Stockholders and Provides Other Corporate Updates
NovaBay Pharmaceuticals Launches Avenova Product Bundles for Individualized Relief from Multifactorial Dry Eye Symptoms
NovaBay Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Earnings Flash (NBY) NOVABAY PHARMACEUTICALS Reports Q1 Revenue $2.63M, vs. Street Est of $3.28M
NovaBay Pharmaceuticals Reports First Quarter 2024 Financial Results
NovaBay Pharmaceuticals Announces Record Ordered Product Sales of Avenova-Branded Products in April through Amazon
NovaBay Pharmaceuticals to Hold 2024 First Quarter Conference Call on May 9, 2024
NovaBay Pharmaceuticals to Hold 2024 First Quarter Conference Call on May 9, 2024
NovaBay Pharmaceuticals Announces New and Enhanced Direct-to-Consumer Marketing to Efficiently Engage Customers and Drive Avenova Sales
NovaBay Pharmaceuticals Receives a NYSE American Notice Regarding Stockholder Equity
NovaBay Pharmaceuticals Reports Preliminary Eyecare and Wound Care Revenue Increased 13% for the First Quarter of 2024 on Lower Sales and Marketing Expenses
NovaBay Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Earnings Flash (NBY) NOVABAY PHARMACEUTICALS Posts Q4 Revenue $3.7M, vs. Street Est of $3.4M
NovaBay Pharmaceuticals Reports 2023 Fourth Quarter and Full Year Financial Results
NovaBay Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
NovaBay Pharmaceuticals : Acquisition/Asset Disposal - Form 8-K
NovaBay Pharmaceuticals to Hold 2023 Fourth Quarter and Full Year Conference Call on March 26, 2024
New Age Investments LLC completed the acquisition of DERMAdoctor, Inc. from NovaBay Pharmaceuticals, Inc..
NovaBay Pharmaceuticals Announces Agreement to Sell its DERMAdoctor Skincare Business Segment, Announces Preliminary Financial Results for Fourth Quarter and Year Ended December 31, 2023
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción NBY
  4. Noticias NovaBay Pharmaceuticals, Inc.
  5. Otros idiomas